% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Keshwani:277887,
author = {K. Keshwani and T. Boterberg and K. Dieckmann and G. O.
Janssens and A. Laprie and B. Timmermann$^*$ and M. N. Gaze},
title = {{R}adical skeletal metastatic site irradiation in high-risk
neuroblastoma: systematic review and proposal for a
randomised trial},
journal = {Journal of Cancer Metastasis and Treatment},
volume = {9},
issn = {2394-4722},
address = {Mumbai},
publisher = {Medknow},
reportid = {DKFZ-2023-01554},
pages = {A27},
year = {2023},
abstract = {Aim: Neuroblastoma has a variable outcome depending on age,
stage, and molecular pathology. Distant metastatic disease
is the central feature of high-risk disease. Recommendations
for irradiating persistent metastatic deposits with curative
intent after systemic therapy vary. It is unclear to what
extent this practice may improve local control or survival.
This study systematically reviewed the evidence for skeletal
metastatic site irradiation and made evidence-based
recommendations for clinical practice. Methods: We
systematically reviewed the literature on radical
radiotherapy of persistent metastases after chemotherapy.
The aim was to determine whether a position could be taken
regarding metastatic site irradiation in combined modality
treatment protocols aiming for a cure and whether
recommendations could be formulated Results: The initial
search yielded 445 results. After the title and abstract
review, 13 full papers were retrieved. Ten papers were found
suitable for data extraction. One additional paper was
identified. All 11 were graded as Centre for Evidence-Based
Medicine Step 4 in quality; there was no high-level
evidence. There are suggestions of benefit for skeletal site
irradiation in high-risk neuroblastoma; however, there is no
certainty, and it was not possible to recommend a particular
treatment policy. Conclusion: We recommend that
consideration is given to a randomised evaluation of the
benefits of radiotherapy to a limited number of residual
post-induction-chemotherapy metastatic sites in good
responders. This practice could be incorporated as an
amendment to existing trials.},
subtyp = {Review Article},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
doi = {10.20517/2394-4722.2022.32},
url = {https://inrepo02.dkfz.de/record/277887},
}